Clinical Research Directory
Browse clinical research sites, groups, and studies.
Antithrombotic Therapy After Coronary Artery Bypass Grafting Combined With Coronary Endarterectomy
Sponsor: China National Center for Cardiovascular Diseases
Summary
Coronary endarterectomy (CE) combined with coronary artery bypass grafting (CABG) can be the final option for achieving complete revascularization in diffuse coronary artery disease patients. Since the exposure of subendothelial tissue to the blood flow after CE, the coagulation cascade can be activated, resulting in the increased risk of graft failure. Therefore, anticoagulation with warfarin in this group of patients might be beneficial. However, evidence is limited. This study aims to compare the clinical outcomes between dual antiplatelet therapy with or without warfarin after CE+CABG.
Official title: Comparison of Antithrombotic Therapy After Coronary Artery Bypass Grafting Combined With Coronary Endarterectomy
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
202
Start Date
2023-04-11
Completion Date
2026-05-30
Last Updated
2025-11-18
Healthy Volunteers
No
Conditions
Interventions
Warfarin
dual antiplatelet therapy combined with warfarin
DAPT
Dual antiplatelet therapy (aspirin plus either clopidogrel or ticagrelor)
CE+CABG
Coronary endarterectomy combined with coronary artery bypass grafting
Locations (1)
Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, Beijing Municipality, China